VEIL.AI’s Post

There's still time to register for our virtual symposium this afternoon, starting at 2:30 PM ET. CANCER DISCOVERY VIRTUAL SYMPOSIUM: REDUCING THE GLOBAL CANCER BURDEN https://lnkd.in/eVRT557g Speakers include Satish Gopal, Bob T. Li, Isabel Mestres, C.S. Premesh and Eric Solary. Moderated by Cancer Discovery Editors-in-chief Lew Cantley and Luis Diaz Event description: We are at a pivotal moment in the fight against cancer. National and international efforts are coalescing around calls to action aimed at dramatically decreasing death from cancer in the coming decades. To mark World Cancer Research Day, the AACR journal Cancer Discovery will convene leading thinkers who are working to reduce cancer deaths globally and in their respective regions. This event aims to explore the unique challenges in different regions to identify areas that need more coordinated attention and to promote greater awareness within the global cancer research community. A live panel will facilitate discussions on how international efforts to understand and combat cancer can potentially be integrated for maximum impact.

👉 It's NOT too late! 👈 Register "now" for today's webinar! https://lnkd.in/gCQY-iiy TODAY, July 10, the American Cancer Society Comprehensive Cancer Initiative team, in partnership with ACS NLCRT, will discuss the impact of stigma on access to cancer screening and provide suggested strategies to reduce this barrier.  Accessing Cancer Care Across the Continuum: Overcoming Stigma as a Barrier to Equitable Lung Cancer Care WEBINAR.  (July 10, 2024, 1 - 2 p.m. ET)   This webinar will provide the opportunity to learn about: ✔ The importance and rationale of person-centered approach to lung cancer screening.   ✔ How to engage diverse community partners into the lung cancer community.   ✔ Recommendations for changing the public discourse around lung cancer to create more equitable lung cancer screening, treatment, and survivorship.   Keynote Speakers: ☑ Dr. Lisa Carter-Bawa, PhD, APRN, ANP-C, FAAN a behavioral scientist focused on understanding the many factors that influence patient-clinician communication. ☑ Dr. Jamie L. Studts, PhD, FSBM professor of medicine-medical oncology at the University of Colorado Denver Register to have quick access to the recording and PPT slides: https://lnkd.in/gCQY-iiy

The fight against cancer demands innovation and collaboration. In 2021, we joined forces with UCLA to tackle the complexities of Ewing sarcoma and explore more precise immunotherapy options. This journey led to the groundbreaking Universal Cancer Vaccine Platform (UCV), designed to target cancer cells with laser focus while minimizing harm to healthy tissue. Our commitment to progress didn't stop there. In 2023, a serendipitous discovery revealed the potential to significantly reduce the cost of CAR-T cell therapy – a powerful but expensive treatment. This birthed the Universal CAR-T Cell Platform, aiming to make this life-saving therapy more accessible. Today, we stand at the forefront of cancer treatment with three promising projects: Ewing sarcoma research, the targeted UCV platform, and the affordable CAR-T platform. This multi-pronged approach has the potential to redefine the way we fight cancer. We remain dedicated to collaborating with UCLA to translate these innovations into tangible benefits for patients, empowering their bodies' natural defenses and improving overall outcomes. Visit us at www.cancervax.com to learn more

Pelotonia 2023 - successful completion of 24 miles! The event is over however the focus is on going. "Cancer is the #2 cause of death in the United States - #2!  In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. The cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality." Reprinted in part from the American Cancer Society Facts and Figures 2023 Over the week end alone I had 3 posts in my feeds of people who had lost their fight with cancer. Research is the key! 100% of the funds raised by a Pelotonia rider goes to innovative cancer research - 100%! One Goal! I ride to end cancer!

We are thrilled to share that Inova Schar Cancer is participating in The National Institutes of Health's newly launched nationwide Cancer Screening Research Network (CSRN) to help identify cancers earlier when they may be easier to treat. This clinical trials network will support the Biden-Harris administration’s Cancer Moonshot℠ initiative by evaluating emerging technologies for cancer screening and prevention, such as blood tests that can screen for several types of cancer. Rebecca Kaltman, M.D., Executive Director at Inova Saville Cancer Screening and Prevention Center, will serve as one of the co-principal investigators for the Virginia CSRN ACCESS Hub. “We are in dire need of new tools to detect more types of cancer at earlier, more treatable stages. We are thrilled to be part of the NCI’s [National Cancer Institute] effort to bring the promise of novel techniques for cancer screening to the people of Virginia through this important collaboration,” Dr. Kaltman said. Learn more about this research initiative: https://bit.ly/3uzKPWP #CancerScreening #CancerResearch #CancerMoonshot

The American Cancer Society kicked off Lung Cancer Awareness Month last week by releasing updated screening recommendations. Given that lung cancer is the leading cause of cancer death in the United States, with an estimated 127,000 deaths expected in 2023 alone, our hope is that these updates lead to earlier detection and improved outcomes.   We’ve already seen positive trends related to incidence rates. Since 2006, lung cancer incidence rate has declined 2.6% per year in men and 1.1% per year in women. As always, there is still work to be done. While this updated guideline is an important step, our efforts extend even further. The American Cancer Society Cancer Action Network (ACS CAN) continues to advocate for tobacco control and expanded access to lung cancer screenings. We are also committed to lung cancer research and are currently funding 77 grants totaling more than $63 million with the vision of ending lung cancer as we know it, for everyone. 

As 2023 draws to a close, we would like to extend our sincere thanks to all our members and everyone in the lung cancer community who has supported us this year. There remains a lot to do to ensure lung cancer moves up the political agenda, but we’ve been energised to see steady progress, with England and Australia both committing to screening programmes in 2023. You can learn more about progress in screening where you are, or in other parts of the world, from our interactive map. As we move into 2024 and beyond, we hope we can continue to support policymakers, clinicians and advocates in highlighting the opportunities available to improve lung cancer outcomes.  https://lnkd.in/eiP58M2t